Candel Therapeutics, Inc. (CADL)
Largest Insider Buys in Sector
CADL Stock Price History Chart
CADL Stock Performance
About Candel Therapeutics, Inc.
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of …
Insider Activity of Candel Therapeutics, Inc.
Over the last 12 months, insiders at Candel Therapeutics, Inc. have bought $0 and sold $1.34M worth of Candel Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Candel Therapeutics, Inc. have bought $7.43M and sold $1.34M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 23,950 shares for transaction amount of $45,984 was made by Martell Christopher (director) on 2022‑12‑09.
List of Insider Buy and Sell Transactions, Candel Therapeutics, Inc.
| 2024-10-15 | Sale | 10 percent owner | 10,412 0.0279% | $6.03 | $62,784 | -8.24% | ||
| 2024-10-14 | Sale | 10 percent owner | 15,000 0.0401% | $6.02 | $90,300 | -5.83% | ||
| 2024-10-11 | Sale | 10 percent owner | 15,000 0.0403% | $6.05 | $90,750 | -2.99% | ||
| 2024-10-03 | Sale | 10 percent owner | 1,800 0.0055% | $6.85 | $12,330 | -10.58% | ||
| 2024-10-02 | Sale | 10 percent owner | 26,988 0.083% | $6.92 | $186,757 | -11.89% | ||
| 2024-10-01 | Sale | 10 percent owner | 6,214 0.0194% | $7.01 | $43,555 | -14.29% | ||
| 2024-07-17 | Sale | Chief Executive Officer | 22,528 0.0746% | $6.47 | $145,815 | -7.61% | ||
| 2024-07-17 | Sale | Chief Scientific Officer | 14,051 0.0465% | $6.47 | $90,947 | -7.61% | ||
| 2024-07-17 | Sale | Chief Technology Officer | 14,851 0.0492% | $6.47 | $96,125 | -7.61% | ||
| 2024-07-17 | Sale | Chief Medical Officer | 10,875 0.036% | $6.47 | $70,390 | -7.61% | ||
| 2024-07-17 | Sale | See Remarks | 9,884 0.0327% | $6.47 | $63,975 | -7.61% | ||
| 2024-07-11 | Sale | Chief Executive Officer | 20,293 0.0713% | $5.97 | $121,218 | 0.00% | ||
| 2024-07-11 | Sale | Chief Scientific Officer | 12,645 0.0445% | $5.97 | $75,534 | 0.00% | ||
| 2024-07-11 | Sale | Chief Technology Officer | 13,330 0.0469% | $5.97 | $79,625 | 0.00% | ||
| 2024-07-11 | Sale | Chief Medical Officer | 9,769 0.0343% | $5.97 | $58,354 | 0.00% | ||
| 2024-07-11 | Sale | See Remarks | 8,897 0.0313% | $5.97 | $53,145 | 0.00% | ||
| 2022-12-09 | director | 23,950 0.0761% | $1.92 | $45,984 | -35.41% | |||
| 2022-12-09 | Chief Executive Officer | 12,935 0.0411% | $1.92 | $24,835 | -35.41% | |||
| 2022-12-09 | director | 35,018 0.1125% | $1.94 | $67,935 | -35.41% | |||
| 2022-12-09 | Chief Technology Officer | 10,358 0.0331% | $1.93 | $19,991 | -35.41% |
Insider Historical Profitability
| Tak Paul Peter | Chief Executive Officer | 330735 1.0308% | $5.37 | 3 | 2 | <0.0001% |
| Barone Francesca | Chief Scientific Officer | 159961 0.4986% | $5.37 | 1 | 2 | <0.0001% |
| Tyagarajan Seshu | Chief Technology Officer | 146049 0.4552% | $5.37 | 2 | 2 | <0.0001% |
| Manning Paul B | 1681000 5.2392% | $5.37 | 2 | 0 | <0.0001% | |
| Martell Christopher | director | 152000 0.4737% | $5.37 | 3 | 0 | <0.0001% |
Institutional Investor Ownership
| Northpond Partners LLC | $3.06M | 6.5 | 1.94M | 0% | +$0 | 0.07 | |
| Sands Capital Ventures LLC | $1.28M | 2.73 | 811,737 | 0% | +$0 | 0.31 | |
| The Vanguard Group | $855,246.00 | 1.82 | 541,295 | +27.14% | +$182,562.66 | <0.0001 | |
| Geode Capital Management | $230,256.00 | 0.49 | 145,706 | +4.63% | +$10,197.53 | <0.0001 | |
| Bridgeway Capital Management | $130,500.00 | 0.28 | 82,595 | -37.71% | -$78,999.94 | <0.01 |